ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 9
Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy
Carsten Niemann, MD, PhD, Arnon Kater, MD, PhD, Othman Al-Sawaf, MD, John F. Seymour, MBBS, FRACP, PhD Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.
Video content above is prompted by the following:
- Briefly comment on ongoing trials evaluating other BCL2i/BTKi combination approaches and the potential role of these in the front-line setting.